骨膜蛋白在慢性肾脏病中的研究现状与展望。
The research status and prospect of Periostin in chronic kidney disease.
机构信息
Department of Health Management Medical Center, The Third Hospital of Jilin University, Changchun, China.
Department of Endocrinology and Metabolism, The Third Hospital of Jilin University, Changchun, China.
出版信息
Ren Fail. 2020 Nov;42(1):1166-1172. doi: 10.1080/0886022X.2020.1846562.
The continuous accumulation of extracellular matrix will eventually lead to glomerular sclerosis, interstitial fibrosis, tubular atrophy and vascular sclerosis, which are involved in the progression of chronic kidney disease (CKD). If these processes can be discovered early and effective interventions given in time, the progression of kidney disease may be delayed. Therefore, exploring new biomarkers and therapeutic targets that can identify CKD at an early stage is urgently needed. In recent years, studies have shown that urine periostin may be used as a marker of early renal tubular injury. And in an animal model experiment of hypertensive nephropathy, periostin is involved in the progression of kidney injury and reflects its progression. Here we review the current progress on the role of periostin in pathologic pathways of kidney system to explore whether periostin is a potential therapeutic target for the treatment of CKD.
细胞外基质的不断积累最终会导致肾小球硬化、间质纤维化、肾小管萎缩和血管硬化，这些都涉及到慢性肾脏病（CKD）的进展。如果这些过程能够及早发现，并及时给予有效的干预，那么肾脏疾病的进展可能会被延缓。因此，迫切需要探索能够在早期识别 CKD 的新生物标志物和治疗靶点。近年来的研究表明，尿骨桥蛋白（periostin）可能可作为早期肾小管损伤的标志物。在高血压肾病的动物模型实验中，骨桥蛋白参与了肾脏损伤的进展，并反映了其进展情况。在这里，我们综述了骨桥蛋白在肾脏系统病理途径中的作用的最新进展，以探讨骨桥蛋白是否是治疗 CKD 的潜在治疗靶点。
Zotero 插件